Thursday May 7, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
J&J's Ottava Just Posted Its First Clinical Data. Here's What It Actually Means for Soft-Tissue Robotics.
For more than two decades, soft-tissue robotic surgery has effectively been one company’s market. Intuitive Surgical received the first FDA clearance for general laparoscopic surgery with the da Vinci system in 2000, and by every reasonable estimate has held onto the clear majority of the global market ever since — most recently around 60 percent, according to GlobalData. Hospitals built training programs around da Vinci, surgeons were trained on da Vinci, and competitors that tried to enter the category mostly faded or remained regional. That has begun to shift — Medtronic’s Hugo received its first U.S. clearance in urology in December 2025, CMR Surgical’s Versius platform crossed 40,000 procedures globally this spring — but the most-watched challenger has been Johnson & Johnson, which announced its Ottava program in 2020 and has been mostly quiet ever since.
On May 5, J&J presented the first clinical data on Ottava at the American Society for Metabolic and Bariatric Surgery annual meeting in San Antonio. The FORTE study enrolled 30 patients across six U.S. hospitals, all of whom were undergoing Roux-en-Y gastric bypass. The system met its primary safety and performance endpoints at 30 days. All 30 procedures were completed robotically without conversion to a non-robotic approach. J&J said the data, combined with preclinical work, support the de novo classification application it submitted to the FDA in January for general surgery, including gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair.
The path to that data has been longer than J&J originally projected. The company unveiled Ottava in 2020, delayed development by approximately two years in late 2021, submitted for an Investigational Device Exemption in October 2024, received FDA approval of that IDE the following month, and completed its first cases in April 2025. The FORTE cohort is a feasibility study, not a pivotal trial, and the 30-day window is a safety threshold rather than a comparative efficacy endpoint. Whatever Ottava ultimately becomes commercially, the May 5 announcement is a milestone inside an FDA submission process — not a market launch.
The Architecture Bet
What separates Ottava from the systems already on the market — and what makes the FORTE results worth a closer look than the headline numbers — is the physical design. Da Vinci, Hugo, and Versius all use cart-based or boom-mounted arms positioned next to the patient. Ottava integrates four robotic arms into a standard-sized surgical table. There is no separate robot to wheel into the room.
In FORTE, the operating rooms ranged from approximately 243 to 694 square feet. According to J&J, in five of the six sites, procedures were performed in ORs that had not previously hosted robotic surgery. That is the strategic claim the company is making: not that Ottava performs better than da Vinci, but that it fits in places da Vinci cannot easily go. Intuitive’s installed base advantage — built up over more than two decades of placements — has rested on the implicit assumption that the hospital adapts to the robot. Ottava is being positioned around the inverse assumption.
That reframing matters because the largest unaddressed segment of soft-tissue robotics is not academic medical centers, where da Vinci is already entrenched. It is the ambulatory surgery centers and community hospitals that have been priced out or space-constrained out of robotic surgery entirely. ASCs have been shifting volume away from inpatient settings for over a decade, and robotic soft-tissue surgery has largely not kept pace. If Ottava can be installed in ORs that smaller facilities already have — and J&J’s data suggests it can — the addressable market for soft-tissue robots looks different from the one Intuitive has spent 25 years building.
The Open Questions
The FORTE data does not establish that Ottava performs as well as da Vinci or as well as Hugo. It establishes that Ottava can safely perform gastric bypass in 30 patients within 30 days. The de novo submission is also broader than what was studied clinically — J&J is asking the FDA to authorize Ottava for procedures not yet evaluated in human trials, supported by preclinical work and the FORTE data as a feasibility benchmark. De novo decisions typically take longer than 510(k) reviews, and the FDA’s device center has been operating with reduced staffing through 2025 and into 2026, which has slowed reviews across the medtech sector.
There are also market headwinds specific to bariatric surgery, the lead indication J&J chose to study. GLP-1 medications have introduced new pressure on surgical weight loss volume over the past two years. Roux-en-Y was a sensible choice for a feasibility study — the procedure is well standardized and well instrumented for robotic comparison — but the long-term commercial argument for Ottava will rest more on its other indications, particularly hernia repair and small bowel resection, and on whatever specialties J&J pursues in subsequent submissions.
The company has not disclosed pricing or a commercial timeline. Intuitive, meanwhile, is two years into the rollout of da Vinci 5, which adds force-feedback instrumentation and computational features the previous generation lacked. The architectural argument Ottava is making is compelling on paper. Whether hospitals — particularly the ASCs and community systems that the system appears implicitly built for — adopt it on those terms is a question the FORTE data does not yet answer.
SPONSORED BY RŌG HEALTH
Most medical device companies don't fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.